Skip to main content

Table 1 Summary characteristics of 2018 Harm Reduction Client Survey participants stratified by using alone in the last 7 days

From: Convenience and comfort: reasons reported for using drugs alone among clients of harm reduction sites in British Columbia, Canada

Characteristics

Did not use alone

(N = 100)

Used alone

(N = 314)

Total

(N = 414)

p value

n (%)

n (%)

n (%)

Age

   

0.16

19–29

16 (16.0%)

64 (20.4%)

80 (19.3%)

 

30–39

22 (22.0%)

95 (30.3%)

117 (28.3%)

 

40–49

30 (30.0%)

78 (24.8%)

108 (26.1%)

 

> 50

32 (32.0%)

76 (24.2%)

108 (26.1%)

 

Gendera

   

0.16

Woman

40 (40.0%)

104 (33.1%)

144 (34.8%)

 

Man

56 (56.0%)

203 (64.6%)

259 (62.6%)

 

Health authority

   

0.23

Fraser

38 (38.0%)

129 (41.1%)

167 (40.3%)

 

Interior

19 (19.0%)

35 (11.1%)

54 (13.0%)

 

Island

23 (23.0%)

68 (21.7%)

91 (22.0%)

 

Northern

10 (10.0%)

50 (15.9%)

60 (14.5%)

 

Vancouver Coastal (rural communities)

10 (10.0%)

32 (10.2%)

42 (10.1%)

 

Urbanicity

   

0.74

Small urban/rural communities

26 (26.0%)

87 (27.7%)

113 (27.3%)

 

Medium/large urban cities

74 (74.0%)

227 (72.3%)

301 (72.7%)

 

Currently regularly housed

   

< 0.01

Yes

74 (74.0%)

186 (59.2%)

260 (62.8%)

 

No

24 (24.0%)

118 (37.6%)

142 (34.3%)

 

Currently employed

   

0.19

Yes

23 (23.0%)

53 (16.9%)

76 (18.4%)

 

No

75 (75.0%)

250 (79.6%)

325 (78.5%)

 

Naloxone kit possession

   

0.61

Yes

66 (66.0%)

213 (67.8%)

279 (67.4%)

 

No

30 (30.0%)

85 (27.1%)

115 (27.8%)

 

Preferred drug use method

   

0.87

Injection

32 (32.0%)

108 (34.4%)

140 (33.8%)

 

Non-injectionb

59 (59.0%)

191 (60.8%)

250 (60.4%)

 

Opioid use (last 7 days)c

   

0.04

Yes

60 (60.0%)

230 (73.2%)

290 (70.0%)

 

No

36 (36.0%)

83 (26.4%)

119 (28.7%)

 

Crystal meth use (last 7 days)

   

< 0.01

Yes

61 (61.0%)

241 (76.8%)

302 (72.9%)

 

No

35 (35.0%)

72 (22.9%)

107 (25.8%)

 

Crack/cocaine use (last 7 days)

   

0.01

Yes

26 (26.0%)

130 (41.4%)

156 (37.7%)

 

No

70 (70.0%)

183 (58.3%)

253 (61.1%)

 

Benzodiazepine use (last 7 days)

   

0.29

Yes

10 (10.0%)

46 (14.6%)

56 (13.5%)

 

No

86 (86.0%)

267 (85.0%)

353 (85.3%)

 

Alcohol use (last 7 days)

   

0.15

Yes

35 (35.0%)

140 (44.6%)

175 (42.3%)

 

No

61 (61.0%)

173 (55.1%)

234 (56.5%)

 

Polysubstance use (last 7 days)d

   

< 0.01

Yes

52 (52.0%)

215 (68.5%)

267 (64.5%)

 

No

44 (44.0%)

98 (31.2%)

142 (34.3%)

 

Experienced an opioid or stimulant overdose (last 6 months)

   

0.03

Yes

15 (15.0%)

72 (22.9%)

93 (22.5%)

 

No

78 (78.0%)

194 (61.8%)

266 (64.3%)

 
  1. Missing values account for percentages which do not add up to 100% or total numbers that do not add up to 414
  2. aOther genders reported included being a trans man, trans woman, or gender non-conforming which are not shown here due to small sample size (n = 9)
  3. bNon-injection methods included smoking/inhaling/snorting (56.5%, n = 234) and other methods (3.9%, n = 16)
  4. cOpioids included heroin, fentanyl, morphine, hydromorphone (Dilaudid), methadone, and oxycodone
  5. dPolysubstance use was defined as concurrent use of opioids & stimulants, opioids & benzodiazepines, or stimulants & benzodiazepines
Back to article page

Harm Reduction Journal

ISSN: 1477-7517